ReviewNature reviews. Immunology2016
Cutaneous leishmaniasis: immune responses in protection and pathogenesis.
Review in Nature reviews. Immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 310 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
310 citing papers in PubMed, 3 syntheses or guidelines pooled it, 577 citations in OpenAlex.
- Global Landscape of Molecular and Immunological Diagnostic Tests for Human Leishmaniasis: A Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2025Pooled it
- The anti-Leishmania potential of bioactive compounds derived from naphthoquinones and their possible applications. A systematic review of animal studies.Parasitology research · 2022Pooled it
- Leishmaniasis and Trace Element Alterations: a Systematic Review.Biological trace element research · 2021Pooled it
- An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil.PLoS neglected tropical diseases · 2021Trial
- An Insight Into Systemic Immune Response inFrontiers in immunology · 2021Trial
- The proteinase-activated receptor-2 mediates protective immunity in early experimental leishmaniasis.Emerging microbes & infections · 2026Article
- microRNA and Regulatory Networks of Human Macrophage DuringInternational journal of molecular sciences · 2026Article
- Cell Death and Unprecedent Cytoskeletal Changes inChemical & biomedical imaging · 2026Article
- Leishmanicidal efficacy of cold atmospheric multiple plasma jet against Leishmania major in a murine model: effects on parasite burden, cytokine profiles, and wound healing.Scientific reports · 2026Article
- LeishVet update and current recommendations on feline leishmaniosis.Parasites & vectors · 2026Review
- A dual-host regulatory hub integrating biofilm formation and innate immunity resistance.Nature communications · 2026Article
- Lymphocyte-mediated immune responses to Leishmania infection.Nature reviews. Immunology · 2026Review
- Immunochemotherapy with Amphotericin B and HisAK70 Vaccine for Cutaneous Leishmaniosis.International journal of molecular sciences · 2026Article
- Bone Marrow-Derived Mesenchymal Stem Cells Alleviate Cutaneous Leishmaniasis by Promoting M2 Macrophage Polarization and Skin Tissue Repair in a Murine Model.Biomolecules · 2026Article
- Platelet DKK1 promotes tolerogenic dendritic cells and non-healing responses in cutaneous leishmaniasis.iScience · 2026Article
- Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond.Signal transduction and targeted therapy · 2026Review
- Article
- Metabolically reprogrammed eosinophils impair T cell immunity and cause chronic skin infection.EMBO molecular medicine · 2026Article
- Brain Involvement in Leishmaniasis.Cell biochemistry and function · 2026Review
- Population pharmacokinetics of DNDI-6148 in healthy adults.PLoS neglected tropical diseases · 2026Article
250 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cutaneous leishmaniasis is a major public health problem and causes a range of diseases from self-healing infections to chronic disfiguring disease. Currently, there is no vaccine for leishmaniasis, and drug therapy is often ineffective. Since the discovery of CD4(+) T helper 1 (TH1) cells and TH2 cells 30 years ago, studies of cutaneous leishmaniasis in mice have answered basic immunological questions concerning the development and maintenance of CD4(+) T cell subsets. However, new strategies for controlling the human disease have not been forthcoming. Nevertheless, advances in our knowledge of the cells that participate in protection against Leishmania infection and the cells that mediate increased pathology have highlighted new approaches for vaccine development and immunotherapy. In this Review, we discuss the early events associated with infection, the CD4(+) T cells that mediate protective immunity and the pathological role that CD8(+) T cells can have in cutaneous leishmaniasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.